ARWR Financials: Arrowhead Pharmaceuticals Inc AI Analysis



Financials

ARWR Financial

Arrowhead Pharmaceuticals Inc

$70.13

-4.71%

$-3.46

At close: Apr 28, 16:00:00 GMT-4

$70.13

Pre-market: Apr 29, 05:20:03 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$73.6

Open

$73.5

Day's Range

$69.49 - $74.49

52 week range

$12.44 - $76.76

Volume

1.5M

Avg.Volume

2.6M

Dividend yield

EPS (TTM)

1.54

Market Cap

$9.8B

What is ARWR?

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The company is headquartered in Pasadena, California and currently employs 711 full-time employees. The firm's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The firm's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. The company is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. The company has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The firm's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.

Features

Markets

News

Income

Balance sheet

Cash flow

Annual

Quarterly

ARWR Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024
Revenue	1,474	624	390	260	199	983
Revenue Growth (YoY)	-18%	-37%	19%	-18%	16%	193%
Cost of Revenue	771	474	124	96	76	651
Gross Profit	703	149	265	164	123	331
Selling, General & Admin	202	58	46	54	42	41
Research & Development	--	--	--	--	--	--
Operating Expenses	401	123	90	98	88	86
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	161	4	158	-15	14	225
Income Tax Expense	37	0	38	-3	3	62
Net Income	123	6	119	-12	10	156
Net Income Growth	-38%	-96%	65%	-157%	-119%	359%
Shares Outstanding (Diluted)	59.32	59.32	59.12	55.32	50.02	50.48
Shares Change (YoY)	18%	18%	19%	11%	1%	2%
EPS (Diluted)	2.08	0.1	2.02	-0.21	0.21	3.09
EPS Growth	-47%	-97%	38%	-152%	-120%	347%
Free Cash Flow	225	301	105	110	-292	245
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	47.69%	23.87%	67.94%	63.07%	61.8%	33.67%
Operating Margin	20.42%	4.16%	44.87%	25.38%	17.08%	24.92%
Profit Margin	8.34%	0.96%	30.51%	-4.61%	5.02%	15.86%
Free Cash Flow Margin	15.26%	48.23%	26.92%	42.3%	-146.73%	24.92%
EBITDA	484	73	221	110	79	289
EBITDA Margin	32.83%	11.69%	56.66%	42.3%	39.69%	29.39%
D&A For EBITDA	183	47	46	44	45	44
EBIT	301	26	175	66	34	245
EBIT Margin	20.42%	4.16%	44.87%	25.38%	17.08%	24.92%
Effective Tax Rate	22.98%	0%	24.05%	20%	21.42%	27.55%

Follow-Up Questions

What are Arrowhead Pharmaceuticals Inc's key financial statements?



According to the latest financial statement (Form-10K), Howard Hughes Holdings Inc has a total asset of $0, Net loss of $0

What are the key financial ratios for ARWR?



Howard Hughes Holdings Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Arrowhead Pharmaceuticals Inc's revenue broken down by segment or geography?



Currently Howard Hughes Holdings Inc data is not available.

Is Arrowhead Pharmaceuticals Inc profitable?



no, according to the latest financial statements, Howard Hughes Holdings Inc has a net loss of $0

Does Arrowhead Pharmaceuticals Inc have any liabilities?



no, Howard Hughes Holdings Inc has liability of 0

How many outstanding shares for Arrowhead Pharmaceuticals Inc?



Howard Hughes Holdings Inc has a total outstanding shares of 0

Arrowhead Pharmaceuticals Inc (ARWR) Financial

ARWR Stock Price Chart